Cytokine Therapy of HIV Infection

  • Michael C. Sneller
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)


Development of new therapeutics for human immunodeficiency virus (HIV) infection is one of the most active areas of medical research today. While the use of antiretrovirals such as zidovudine has improved survival, these drugs have not been able to halt the progressive destruction of the immune system that characterizes HIV infection. Thus, any design of a comprehensive therapeutic strategy for HIV disease must focus not only on blocking viral replication, but also on restoring immunocompetence. This review will focus on past and current strategies for using cytokine therapy to achieve these goals.


Human Immunodeficiency Virus Natural Killer Human Immunodeficiency Virus Type Acquire Immunodeficiency Syndrome Cytokine Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baron S, Tyring SK, Fleischmann WJ, et al., The interferons. Mechanisms of action and clinical applications, JAMA, 1991; 266: 1375–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Pitha PM, Wivel NA, Femie BF, et al., Effect of interferon and mucine leukaemia virus infection. IV. Formation of non-infectious virus in chronically infected cells, J Gen Virol, 1979; 42: 467–480.PubMedCrossRefGoogle Scholar
  3. 3.
    Ho DD, Hartshorn KL, Rota TR, et al., Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro, Lancet, 1985;i:602–604.Google Scholar
  4. 4.
    Poli G, Orenstein JM, Kinter A, et al., Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines, Science, 1989; 244: 575–577.PubMedCrossRefGoogle Scholar
  5. 5.
    Francis ML, Meltzer MS, Gendelman HE, Interferons in the persistence, pathogenesis, and treatment of HIV infection, Aids Res Hum Retroviruses, 1992; 8: 199–207.PubMedCrossRefGoogle Scholar
  6. 6.
    deWit R, Schattenkerk JK, Boucher CA, et al., Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi’s sarcoma, Lancet, 1988;ii:1218–1222.Google Scholar
  7. 7.
    Lane HC, Kovacs JA, Feinberg J, et al., Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi’s sarcoma., Lancet, 1988; 2: 1218–1222.PubMedCrossRefGoogle Scholar
  8. 8.
    Volberding PA, Mitsuyasu R, Recombinant interferon-alpha in the treatment of acquired immune deficiency syndrome related KS, Seiminars Oncol, 1985; 12: 2–6.Google Scholar
  9. 9.
    Gelmann EP, Preble OT, Steis R, et al, Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters, Am J Med, 1985; 78: 737–411.PubMedCrossRefGoogle Scholar
  10. 10.
    Groopman JE, Gottlieb MS, Goodman J, et al., Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome, Arm Intern Med, 1984; 100: 671–663.CrossRefGoogle Scholar
  11. 11.
    Real FX, Oettgen HF, Krown SE, Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon, J Clin Oncol, 1986; 4: 544–512.PubMedGoogle Scholar
  12. 12.
    Lane HC, Davey V, Kovacs JA, et al., Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial., Ann Intern Med, 1990; 112: 805–811.PubMedCrossRefGoogle Scholar
  13. 13.
    Jonhson VA, Barlow MA, Merrill DP, et al., Three-drug syngergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-a, J Infect Dis, 1990; 161: 1059–1067.CrossRefGoogle Scholar
  14. 14.
    Kovacs JA, Deyton L, Davey R, et al., Combined zidovudine and interferon-a therapy in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndrome (AIDS), Ann Intern Med, 1989; 111: 280287.Google Scholar
  15. 15.
    Edlin BR, Weinstein RA, Whaling SM, et al., Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction, J Infect Dis, 1992; 165: 793–798.PubMedCrossRefGoogle Scholar
  16. 16.
    Fisch’ MA, Uttamchandani RB, Resnick L, et al., A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha nl and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma, J Acquir Immune Defic Syndr, 1991; 4: 1–10.Google Scholar
  17. 17.
    Krown SE, Gold JW, Niedzwiecki D, et al., Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS), Ann Intern Med, 1990; 112: 812–821.PubMedCrossRefGoogle Scholar
  18. 18.
    Berglund O, Engman K, Ehrnst A, et al., Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine, J Infect Dis, 1991; 163: 710–715.PubMedCrossRefGoogle Scholar
  19. 19.
    Hartshorn K, Neumeyer D, Vogt M, et al., Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro, AIDS Res Hum Retroviruses, 1987; 112: 582–589.Google Scholar
  20. 20.
    Miles SA, Wang HJ, Cortes E. et al., Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infectio, Ann Intern Med, 1990; 112: 58 2589.Google Scholar
  21. 21.
    Lane HC, Davey RT, Sherwin SA, et al., Phase I trial of recombinant interferon-gamma in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndrome (AIDS). J. Clin. Immunol., 1989; 9: 351–361.PubMedCrossRefGoogle Scholar
  22. 22.
    Murray HW, Welte K, Jacobs JL, et al., Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome., J Clin Invest, 1985; 76: 1959–1964.PubMedCrossRefGoogle Scholar
  23. 23.
    Ciobanu N, Kruger G, Welte K, Defective T cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin-2, J Clin Immunol, 1983; 3: 332–340.PubMedCrossRefGoogle Scholar
  24. 24.
    Gupta S, Study of activated T cells in man: Interleukin-2 receptor and transferrin receptor expression on T cells and production of interleukin-2 in patients with acquired immune deficiency syndrome, Clin Immunol Immunopathol, 1986; 38: 93–100.PubMedCrossRefGoogle Scholar
  25. 25.
    Clerici M, Hakim FT, Venzon DJ, et al., Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals., J Clin Invest, 1993; 91: 759–765.PubMedCrossRefGoogle Scholar
  26. 26.
    Rook AH, Hooks JJ, Quinnan GV, et al., Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism, J Immunol, 1985; 134: 1503–1507.PubMedGoogle Scholar
  27. 27.
    Ernst M, Kern P, Flad HD, et al., Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome and AIDS-related complex on phenotypes and functions of peripheral blood mononuclear cells, J Clin Immunol, 1986; 6: 170–181.PubMedCrossRefGoogle Scholar
  28. 28.
    Kern P, Toy J, Dietrich M, Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS, Blut, 1985; 50: 1–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Lane HC, Siegel JP, Rook AH, et al., Use of interleukin-2 in patients with acquired immunodeficiency syndrome, J Biol Response Mod, 1984; 3: 512–516.PubMedGoogle Scholar
  30. 30.
    Schwartz DH, Skowron G, Merigan TC, Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus., J Acquir Immune Defic Syndr, 1991; 4: 11–23.PubMedCrossRefGoogle Scholar
  31. 31.
    Wood R, Montoya JG, Kundu SK, et al., Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study, J Infect Dis, 1993; 167: 519–525.PubMedCrossRefGoogle Scholar
  32. 32.
    McMahon DK, Armstrong JA, Huang XL, et al., A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine, AIDS, 1994; 8: 59–66.PubMedCrossRefGoogle Scholar
  33. 33.
    Waites L, Fyfe G, Senechek D, et al., Polyethylene glycol modified interleukin-2 (PEG IL-2) therapy in HIV seropositive individuals [abstract no. PuB 7580], In: Program and abstracts: VIII International Conference on AIDS ( Amsterdam ), Congrex Holland BV, 1992.Google Scholar
  34. 34.
    Teppler H, Kaplan G, Smith K, et al., Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection, J Infect Dis, 1993; 167: 291–298.PubMedCrossRefGoogle Scholar
  35. 35.
    Teppler H, Kaplan G, Smith KA, et al., Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection, J Exp Med, 1993; 177: 483–492.PubMedCrossRefGoogle Scholar
  36. 36.
    Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995; 332: 567–975.PubMedCrossRefGoogle Scholar
  37. 37.
    Paul W, Seder R, Lymphocyte responses and cytokines, Cell, 1994; 76: 241–251.PubMedCrossRefGoogle Scholar
  38. 38.
    Clerici M, Shearer G, A Thl-Th2 switch is a critical step in the etiology of HIV infection, Imunol Today, 1993; 14: 107–110.CrossRefGoogle Scholar
  39. 39.
    Maggi E, Mazzetti M, Ravina A, et al., Ability of HIV to promote a TH1 to THO shift and to replicate preferentially in TH2 and THO cells, Science, 1994; 265: 244–248.PubMedCrossRefGoogle Scholar
  40. 40.
    Graziosi C, Pantaleo G, Gantt KR, et al., Lack of evidence for the dichotomy of TH 1 and TH2 predominance in HIV-infected individuals, Science, 1994; 265: 248–252.PubMedCrossRefGoogle Scholar
  41. 41.
    Chehimi J, Starr SE, Frank I, et al., Impaired interleukin 12 production in human immunodeficiency virus-infected patients, J Exp Med, 1994; 179: 1361–1368.PubMedCrossRefGoogle Scholar
  42. 42.
    Chehimi J, Starr SE, Frank I, et al., Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients, J Exp Med, 1992; 175: 789–796.PubMedCrossRefGoogle Scholar
  43. 43.
    Clerici M, Lucey DR, Berzofsky JA, et al., Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro, Science, 1993; 262: 1721–1724.PubMedCrossRefGoogle Scholar
  44. 44.
    Rieckmann P, Poli G, Fox CH, et al., Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors, J Immunol, 1991; 147: 2922–2927.PubMedGoogle Scholar
  45. 45.
    Rieckmann P, Poli G, Kehrl JH, et al., Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, UI, J Exp Med, 1991; 173: 1–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Poli G, Kinter A, Justement J, et al., Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression, Proc Natl Acad Sci USA, 1990; 87: 782–785.PubMedCrossRefGoogle Scholar
  47. 47.
    Sampaio EP, Moreira AL, Sarno EN, et al., Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients, J Exp Med, 1992; 175: 1729–1737.PubMedCrossRefGoogle Scholar
  48. 48.
    Fazely F, Dezube BJ, Allen RJ, et al., Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells, Blood, 1991; 77: 1653–1656.PubMedGoogle Scholar
  49. 49.
    Howard OM, Clouse KA, Smith C, et al., Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation, Proc Natl Acad Sci U S A, 1993; 90: 2335–2339.PubMedCrossRefGoogle Scholar
  50. 50.
    Murray HW. Inteferon-gamma therapy in AIDS for mononuclear phagocyte activation. Biotherapy, 1990; 2: 149–158.PubMedCrossRefGoogle Scholar
  51. 51.
    Smith KA. Interleukin-2: inception, impact and implications. Science, 1988; 240: 1169–1176.PubMedCrossRefGoogle Scholar
  52. 52.
    Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell, 1994; 76: 241–151.PubMedCrossRefGoogle Scholar
  53. 53.
    Beutler B, Cerami A. The biology of cachectin/INF-a primary mediator of the host response. Annu Rev Immunol, 1989; 7: 625–655.PubMedCrossRefGoogle Scholar
  54. 54.
    Dezube BJ, Pardee AB, Beckett LA et al. Cytokine dysregulation in AIDS: in vivo overexpression of mRNA of tumor necrosis factor-alpha and its correlation with that of the inflammatory cytocine GRO. J Acquir Immune Defic Syndr, 1992; 5: 1099–1104.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Michael C. Sneller

There are no affiliations available

Personalised recommendations